Interferon‐α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus‐related hepatocellular carcinoma

Qu, Lei; Jin, Fei; Huang, Xiaowu; Shen, Xin

doi:10.1002/jso.21741

Cited by 33 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the case-control studies that have been reported, 5 are related to hepatitis C [11,12,13] and 2 are related to hepatitis B-related HCC [15,17]. In all of these studies, the recurrence or survival rate was evaluated similarly to RCTs, and significant differences were found in the survival rate with a prolonged duration of IFN administration or the observation period (fig.…”

Section: Low-dose Long-term Ifn Therapy (Ifn Maintenance Therapy) Tomentioning

confidence: 99%

“…Also, the recurrence rate of HBV-related HCC as well as the hazard ratio have been reported to be lower in an IFN-treated group than in a non-IFN-treated group [15]. IFN administration has also been reported to increase the overall survival rate [17]. These results suggest that IFN prevents recurrence by suppressing inflammation or by its direct anticancer effect not only in hepatitis C patients but also in patients with hepatitis B.…”

Section: Low-dose Long-term Ifn Therapy (Ifn Maintenance Therapy) Tomentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

Kudo

2011

Oncology

View full text Add to dashboard Cite

It is widely accepted that hepatocellular carcinoma (HCC) has an annual recurrence rate of approximately 15–20% even after potentially curative treatment, with the 5-year recurrence rate reaching 80–90%. This recurrence rate is also known to be similar after various curative treatments including resection, percutaneous ethanol injection therapy, and radiofrequency ablation. Generally, in treating patients with HCC associated with hepatitis C or liver cirrhosis, aggressive efforts to prevent secondary carcinogenesis are necessary rather than simply observing the clinical course after treatment. Presently, a combination of peg-interferon and ribavirin is known to be highly effective in patients with difficult-to-treat hepatitis C with a high viral load and genotype I virus. Therefore, indications of these treatments must be considered to prevent secondary carcinogenesis in patients with hepatitis C. Recently, long-term follow-up of low-dose, long-term maintenance therapy using pegylated interferon-α2a for cirrhotic patients clearly showed a preventive effect on HCC occurrence and recurrence. Preventing secondary carcinogenesis by suppressing inflammation employing the same treatment as that against primary carcinogenesis is also important. The molecular targeted agent sorafenib markedly suppresses the serine/threonine kinases of Raf in the MAP kinase cascade and inhibits the tyrosine kinases of angiogenesis factor receptors such as vascular endothelial growth factor and platelet-derived growth factor receptors. It thus simultaneously prevents the proliferation of tumors and inhibits angiogenesis. A clinical trial to examine the recurrence-preventing effect of sorafenib by administration of it after curative treatment such as resection or ablation is in progress (STORM trial: http://clinicaltrials.gov.com, NCT00692770). Treatments to prevent recurrence (including intrahepatic metastasis and multicentric carcinogenesis) as well as early detection and early curative treatment are extremely important to improve the prognosis of patients with HCC. Thus, further research on this issue should be carried out, especially in relation to molecular targeted therapy.

show abstract

Section: Low-dose Long-term Ifn Therapy (Ifn Maintenance Therapy) Tomentioning

confidence: 99%

Section: Low-dose Long-term Ifn Therapy (Ifn Maintenance Therapy) Tomentioning

confidence: 99%

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

Kudo

2011

Oncology

View full text Add to dashboard Cite

show abstract

“…Much hope for controlling HCC is placed with active prophylaxis before its occurrence. Fortunately, the occurrence and recurrence of HBV-related HCC can be reduced via active prophylaxis using anti-HBV treatments with nucleos(t)ide analogue (NA) and/or IFNa (4)(5)(6)(7)(8)(9)(10). It is, therefore, important to identify the HBV-infected patients who are more likely to develop HCC, allowing timely intervention in those who will benefit most.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study

Yin

Wang

et al. 2015

Cancer Prevention Research

View full text Add to dashboard Cite

We aimed to evaluate whether hepatitis B virus (HBV) mutations at the core promoter region could improve the prediction and specific prophylaxis of hepatocellular carcinoma (HCC) in chronic HBV-infected patients. A total of 2,114 HBV-infected patients enrolled between August 1998 and December 2007 were followed-up for 18,406 person-years. Of those, 612 received !48 week treatments with nucleos(t)ide analogue (NA) and/or IFNa.

show abstract

“…The protective effect was more prominent in HBeAg-positive Asian patients with chronic hepatitis B [21,22,23,24]. In a recent retrospective case-control study including 317 patients, patients treated with interferon-α had a reduced recurrence rate (p = 0.041) and overall survival (p = 0.009) after resection [25]. In another small-scale RCT [26], adjuvant interferon treatment was only of benefit in advanced-stage HCC after resection.…”

Section: Current Options For the Prevention Of Recurrence After Curatmentioning

confidence: 99%

Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment

Jeng

Lin

Chen

et al. 2014

Dig Dis

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a common malignancy in the world. Although resection and various locoregional therapies can achieve eradication or complete ablation of small HCC, HCC recurrence after these therapies is still common. Although candidates for medical ablation usually exhibit compensated hepatic functional status, the frequent recurrence of HCC after successful ablation contributes to short survival. Therefore, attempts to prevent HCC recurrence are essential to prolong survival. Efforts in preventing HCC recurrence after curative therapies include prevention of early recurrence by improving liver immunity and eliminating microscopic tumor foci or micrometastases, and prevention of late recurrence by reducing the hepatitis activity and using antiviral therapies based on viral suppression/eradication. In HCC with vascular invasion, adjuvant transcatheter arterial chemoembolization should be considered to provide better control. Whether the adjuvant use of sorafenib may suppress microscopic tumor foci or micrometastases may be unveiled in the near future. This review article will update the algorithms, novel medication or study drugs in the prevention of HCC after curative therapies.

show abstract

Interferon‐α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus‐related hepatocellular carcinoma

Abstract: IFN-α therapy after curative resection prevented early recurrence and improved overall survival of patients with HBV-related HCC.

Cited by 33 publications

References 34 publications

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

Adjuvant Therapy after Curative Treatment for Hepatocellular Carcinoma

Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study

Adjuvant Therapy for Hepatocellular Carcinoma after Curative Treatment

Contact Info

Product

Resources

About